Insider Trading November 10, 2026 06:30 PM

American Healthcare REIT Director Estes Offloads $148,300 in Shares Near 52-Week High

The sale by Scott A. Estes comes as AHR stock trades close to its peak and after a strong third-quarter earnings report.

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
AHR

Scott A. Estes, a director at American Healthcare REIT, Inc. (NYSE: AHR), sold 2,500 shares of the company's common stock on November 10, 2026, at $59.32 per share, for a total of $148,300. The transaction occurred as the stock trades near its 52-week high of $59.53 and has delivered a 28% year-to-date return. Following the sale, Estes directly holds 18,989 shares. The article also notes that the stock appears overvalued relative to its Fair Value according to InvestingPro analysis, and it summarizes recent positive developments for the company, including strong third-quarter results with normalized funds from operations up 31.8% to $0.58 per diluted share, revenue of $742.15 million, a raised full-year outlook, and a new $1.75 billion at-the-market equity program. Additionally, RBC Capital and Raymond James have recently raised their price targets for AHR.

American Healthcare REIT Director Estes Offloads $148,300 in Shares Near 52-Week High
AHR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Director Scott A. Estes sold 2,500 shares of American Healthcare REIT at $59.32 per share, totaling $148,300, near the stock's 52-week high of $59.53.
  • The sale occurs after AHR stock has delivered a 28% year-to-date return and as InvestingPro analysis suggests the stock appears overvalued relative to its Fair Value.
  • American Healthcare REIT recently reported strong third-quarter results with normalized FFO up 31.8% to $0.58 per diluted share, revenue of $742.15 million, and raised its full-year outlook.
  • The company launched a $1.75 billion at-the-market equity program, and analysts at RBC Capital and Raymond James have recently raised their price targets for the stock.

American Healthcare REIT, Inc. (NYSE: AHR) disclosed that one of its directors, Scott A. Estes, sold 2,500 shares of the company's common stock on November 10, 2026. The shares were sold at a price of $59.32 per share, resulting in a total transaction value of $148,300.

The sale took place as the stock trades near its 52-week high of $59.53. Year-to-date, shares of American Healthcare REIT have delivered a strong return of 28%. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value, placing it among companies on the Most Overvalued list.

Following this transaction, Mr. Estes directly holds 18,989 shares of American Healthcare REIT common stock. For deeper insights into AHR's valuation and performance, investors can access a comprehensive Pro Research Report, available for this and more than 1,400 other US equities on InvestingPro.

In other recent news, American Healthcare REIT reported strong third-quarter results, with normalized funds from operations increasing by 31.8% to $0.58 per diluted share compared to the previous year. The company also announced revenue of $742.15 million and raised its full-year outlook, highlighting robust performance across its senior housing and skilled nursing platforms. Additionally, American Healthcare REIT launched a $1.75 billion at-the-market equity program, allowing for the sale of common stock through various financial institutions based on market conditions.

RBC Capital raised its price target for American Healthcare REIT to $66 from $61, maintaining an Outperform rating and increasing its funds from operations estimates for 2026, 2027, and 2028. Similarly, Raymond James increased its price target to $72 from $62, maintaining a Strong Buy rating, which reflects confidence in the company's position within the senior housing sector. These developments underscore American Healthcare REIT's growth outlook and platform strength.

Risks

  • The sale by a director may be perceived by some investors as a signal of reduced confidence, potentially putting pressure on the stock price, though insider sales can occur for various reasons.
  • InvestingPro analysis indicates the stock appears overvalued relative to its Fair Value, suggesting a risk of price correction if the market reassesses its valuation.
  • The launch of a $1.75 billion at-the-market equity program could lead to share dilution, which might negatively impact existing shareholders.

More from Insider Trading

Arthur J. Gallagher CHRO Offloads $4.24 Million in Shares Following Option Exercise Nov 10, 2026 indie Semiconductor CFO Offloads $68,000 in Stock Under Pre-Set Trading Plan Nov 10, 2026 Silvaco Director Tewksbury Offloads $7,142 in Shares as Stock Rebounds Nov 10, 2026 Silvaco Director Bo-Linn Cheemin Executes Planned Stock Sale, Receives Equity Award Nov 10, 2026 Tapestry Executive Sells $1.5 Million in Stock After Option Exercise Nov 10, 2026